Novel Cellular Phenotype Screening Method
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/JP2021/000735, filed Jan 12, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,643,649 | Novel Cellular Phenotype Screening Method In force · High confidence | Thinkcyte, Inc., The University of Tokyo and RIKEN | In force | High confidence | ||
| US 12,644,203 | Novel Cellular Phenotype Screening Method In force · Medium confidence | Thinkcyte, Inc., The University of Tokyo and RIKEN | In force | Medium confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.